http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015023824-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1763f7f78d01cad638210d060676591a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16371 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2014-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5c04d54d8a52c66ae4414674f4644a2 |
| publicationDate | 2015-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2015023824-A2 |
| titleOfInvention | Cell permeable inhibitors of the scaffold protein plenty of sh3 domains (posh) or sh3rfl |
| abstract | Here, we identify Plenty of SH3 (POSH) and JNK-interacting protein 1 (JIP-1) as a multi-protein scaffold network for TCR-mediated JNK1 activation in CD 8 + T-cells. Disruption of the POSH/JIP-1 complex led to profound defects in the activation of JNK1, as well as deficient activation or induction of the transcription factors c-Jun, T-bet and Eomesodermin. Furthermore, disruption of the POSH/JIP complex in CD8+ T-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors. Collectively, these data identify a mechanism for the specific regulation of TCR-dependent JNK1 activation and function that is key for CD 8 + T-cell responses. The present invention describes a group of compounds that individually or in concert target a common set of biological pathways important in T cell function, activation of innate inflammation, ischemic reperfusion injury, HIV release and oncogenesis. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11286489-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017139746-A1 |
| priorityDate | 2013-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 334.